# Allergy Therapeutics B301 Phase III results highly statistically significant

- Link: https://www.directorstalkinterviews.com/allergy-therapeutics-b301-phase-iii-results-highly-statistically-significant/412769791
- Published: 2019-03-18T07:16:32+00:00
- Author: Giles Arbor

**Allergy Therapeutics plc** ([LON: AGY](https://www.directorstalkinterviews.com/company/allergy-therapeutics/agy.l)),
the fully integrated commercial biotechnology company specialising in allergy vaccines,
has today announced top-line results from the Phase III clinical trial B301of its
new adjuvanted birch allergoid product. The trial did not show a statistically significant
difference between active and placebo arms in the primary endpoint of a combined
symptom medication score averaged over the peak birch pollen season. The safety 
and tolerability profile was positive and consistent with that observed in previous
trials. Importantly, secondary endpoint analyses of immunoglobulin markers including
IgG and IgG4 showed highly statistically significant differences between active 
and placebo, suggesting a strong and sustained immune response to treatment (p <
0.0001).

Manuel Llobet, CEO at Allergy Therapeutics, stated: “We are surprised by the result,
given the strong immune response suggested by the increased immunoglobulin markers
in the treatment arm and the substantial symptom improvement we had observed in 
earlier trials. We will now undertake a comprehensive review of the full dataset
to determine our path forward with the investigational product. As a science-driven
company we are conscious at Allergy Therapeutics of the challenges regarding subjective
measures in allergy field studies. We are committed to overcoming these challenges
and bringing this new product to market.”

Allergy Therapeutics plc has extensive experience with other approved and commercialized
birch products. Since 2010, the investigational product has undergone two successful
Phase II trials where a highly statistically significant 32% reduction in allergic
symptoms between the active and placebo was observed. The Group will undertake a
review of the full trial dataset to understand any cause for the lack of consistency
in the clinical outcomes seen between the studies.

The B301 trial was a multi-centre, double-blind, placebo-controlled study designed
to test the efficacy in birch-pollen induced seasonal allergic rhinitis. The European
study took place in Germany, Poland, Austria and Sweden with 582 patients over 59
centres being randomised into active and placebo arms, to evaluate the safety and
efficacy measured as a reduction in allergic symptoms as determined by the combined
symptom medication score.

Share on:
